
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros is predicted to experience growth in the coming years, with a strong financial outlook and promising development programs for complement-mediated diseases, cancers, and addictive or compulsive disorders. Recent developments, such as the approval and launch of YARTEMLEA and progress in reimbursement infrastructure, show potential for rapid demand acceleration and efficient conversion from clinical interest to utilization, making this an opportune time for potential investment. However, potential risks include clinical and regulatory, partnership, financial, commercial, legal and intellectual property, and market share risks, as well as scrutiny of Omidria royalties outside of the US and the current high treatment cost of Omeros' products.
Bears say
Omeros is facing challenges with their newly approved TA-TMA therapy, as there is limited clinical data supporting its effectiveness and competition from other treatments. The permanent product-specific J-code from CMS is a positive development, but it does not change the lack of data and potential reimbursement issues that may arise. Additionally, the expected regulatory decision from the EMA in mid-2026 and early utilization trends will be important to monitor, as well as any management commentary on initial launch metrics and commercial infrastructure as disclosed on upcoming earnings calls.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares